Small cell lung cancer responds to immunogenic chemotherapy followed by PD-1 blockade

Sequential combination of immunogenic cell death (ICD)-induced interventions with subsequent immunotherapy has shown efficacy in preclinical models and clinical evaluation. Recently, a clinical trial enrolling small cell lung cancer patients treated with amrubicin together with PD-1 blockade confirm...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Guido Kroemer, Oliver Kepp
Formato:	article
Lenguaje:	EN
Publicado:	Taylor & Francis Group 2021
Materias:	immunotherapy anthracycline lung cancer Immunologic diseases. Allergy RC581-607 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/c51fb2797cc54bd2a0fe9b6c95667874
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:c51fb2797cc54bd2a0fe9b6c95667874
record_format	dspace
spelling	oai:doaj.org-article:c51fb2797cc54bd2a0fe9b6c956678742021-11-04T15:00:45ZSmall cell lung cancer responds to immunogenic chemotherapy followed by PD-1 blockade2162-402X10.1080/2162402X.2021.1996686https://doaj.org/article/c51fb2797cc54bd2a0fe9b6c956678742021-01-01T00:00:00Zhttp://dx.doi.org/10.1080/2162402X.2021.1996686https://doaj.org/toc/2162-402XSequential combination of immunogenic cell death (ICD)-induced interventions with subsequent immunotherapy has shown efficacy in preclinical models and clinical evaluation. Recently, a clinical trial enrolling small cell lung cancer patients treated with amrubicin together with PD-1 blockade confirmed the notion that ICD sensitizes tumors to immune checkpoint inhibitors.Guido KroemerOliver KeppTaylor & Francis Grouparticleimmunotherapyanthracyclinelung cancerImmunologic diseases. AllergyRC581-607Neoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENOncoImmunology, Vol 10, Iss 1 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	immunotherapy anthracycline lung cancer Immunologic diseases. Allergy RC581-607 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	immunotherapy anthracycline lung cancer Immunologic diseases. Allergy RC581-607 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Guido Kroemer Oliver Kepp Small cell lung cancer responds to immunogenic chemotherapy followed by PD-1 blockade
description	Sequential combination of immunogenic cell death (ICD)-induced interventions with subsequent immunotherapy has shown efficacy in preclinical models and clinical evaluation. Recently, a clinical trial enrolling small cell lung cancer patients treated with amrubicin together with PD-1 blockade confirmed the notion that ICD sensitizes tumors to immune checkpoint inhibitors.
format	article
author	Guido Kroemer Oliver Kepp
author_facet	Guido Kroemer Oliver Kepp
author_sort	Guido Kroemer
title	Small cell lung cancer responds to immunogenic chemotherapy followed by PD-1 blockade
title_short	Small cell lung cancer responds to immunogenic chemotherapy followed by PD-1 blockade
title_full	Small cell lung cancer responds to immunogenic chemotherapy followed by PD-1 blockade
title_fullStr	Small cell lung cancer responds to immunogenic chemotherapy followed by PD-1 blockade
title_full_unstemmed	Small cell lung cancer responds to immunogenic chemotherapy followed by PD-1 blockade
title_sort	small cell lung cancer responds to immunogenic chemotherapy followed by pd-1 blockade
publisher	Taylor & Francis Group
publishDate	2021
url	https://doaj.org/article/c51fb2797cc54bd2a0fe9b6c95667874
work_keys_str_mv	AT guidokroemer smallcelllungcancerrespondstoimmunogenicchemotherapyfollowedbypd1blockade AT oliverkepp smallcelllungcancerrespondstoimmunogenicchemotherapyfollowedbypd1blockade
_version_	1718444797029515264

Small cell lung cancer responds to immunogenic chemotherapy followed by PD-1 blockade

Ejemplares similares